In the fall of 2008, Tethys Bioscience acquired Lipomics Technologies, a Taraval Funds portfolio company that provided proprietary lipid diagnostic services for diagnosing metabolic disorders, including diabetes, cardiovascular disease associated with menopause, and pathological side effects induced by drug treatments. The Company built and operated an analytical laboratory that produces proprietary "lipomic" data on 500 individual lipid metabolites from a small sample of blood or tissue.

Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers – biomarkers – that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that use protein and other blood borne biomarkers, and now lipid metabolites, to identify people at high risk for devastating and preventable diseases, the combined companies arm patients and physicians with knowledge they can use to help prevent disease progression.